XML 22 R12.htm IDEA: XBRL DOCUMENT
v3.25.3

Balance Sheet Components | 9 Months Ended
--- | ---
Sep. 30, 2025
Balance Sheet Components |
Balance Sheet Components | 5. Balance Sheet Components Property and Equipment, Net Property and equipment, net of continuing operations consisted of the following:
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | September 30, | ​ | December 31,
(in thousands) | ​ | 2025 | ​ | 2024
Machinery and equipment | ​ | $ | 12,055 | ​ | $ | 13,437
Computer equipment and software | ​ |  | 2,158 | ​ |  | 3,582
Furniture and fixtures | ​ |  | 1,005 | ​ |  | 1,055
Leasehold improvements | ​ |  | 5,751 | ​ |  | 5,751
Total property and equipment | ​ |  | 20,969 | ​ |  | 23,825
Accumulated depreciation and amortization | ​ |  | (19,336) | ​ |  | (20,988)
Property and equipment, net - including discontinued operations | ​ | ​ | 1,633 | ​ | ​ | 2,837
Less: Property and equipment, net from discontinued operations | ​ | ​ | — | ​ | ​ | (261)
Property and equipment, net | ​ | $ | 1,633 | ​ | $ | 2,576
​ Depreciation and amortization expense related to property and equipment, net was $0.3 million and $1.0 million for the three and nine months ended September 30, 2025, respectively, and $0.4 million and $1.5 million for the three and nine months ended September 30, 2024, respectively. ​ As of September 30, 2025 and December 31, 2024, the net book value of software implementation costs of continuing operations related to hosting arrangements was $0.7 million and $1.7 million, respectively, and the amortization expense was immaterial for all periods presented. ​ Intangible Assets, Net Continuing operations intangible assets, net consisted of the following: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | September 30, | ​ | December 31,
(in thousands) | ​ | 2025 | ​ | 2024
Finite-lived assets, net of accumulated amortization of $4,375 and $2,719, as of September 30, 2025 and December 31, 2024, respectively | ​ | $ | 20,625 | ​ | $ | 24,787
Indefinite-lived assets - in-process research and development | ​ | ​ | 28,859 | ​ | ​ | 28,859
Total Intangible assets, net | ​ | $ | 49,484 | ​ | $ | 53,646
​ Amortization expense related to finite-lived intangible assets was $0.7 million and $2.0 million in the three and nine months ended September 30, 2025, respectively, and $1.1 million and $2.7 million in the three and nine months ended September 30, 2024, respectively. ​ The exclusive out-license of GSK4381562 to GlaxoSmithKline Intellectual Property No. 4 Limited (“GSK”), acquired as part of the Surface Acquisition, was terminated by GSK with an effective date of December 16, 2025. As a result, during the third quarter of 2025, the Company recognized a net impairment charge of $1.6 million in selling, general and administrative expenses in the condensed consolidated statements of operations relating to the write-off of the net carrying value of the GSK out-license intangible asset of $2.1 million and the final remeasurement of the CVR liability related to GSK4381562 of $0.5 million to its fair value of zero. ​ The out-licensed partnership program with Novartis Institutes for Biomedical Research, Inc. (“Novartis Institutes”) (NZV930), also acquired as part of the Surface Acquisition, was terminated by Novartis Institutes with an effective date of October 2, 2024. As a result, during the first quarter of 2024, the Company recognized a net impairment charge of $6.8 million in selling, general and administrative expenses in the condensed consolidated statements of operations relating to the write-off of the net carrying value of the Novartis Institutes out-license intangible asset of $10.6 million and the final remeasurement of the CVR liability related to NZV930 of $3.8 million to its fair value of zero. ​ Accrued and Other Current Liabilities Accrued and other current liabilities of continuing operations consisted of the following:
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | September 30, |  | December 31,
(in thousands) | ​ | 2025 | ​ | 2024
Accrued commercial and research and development manufacturing | ​ | $ | 4,207 | ​ | $ | 12,449
Accrued co-development costs and milestone payments | ​ | ​ | — | ​ | ​ | 12,500
Royalty fee derivative liability, current | ​ | ​ | — | ​ | ​ | 13,620
Accrued other | ​ |  | 7,103 | ​ |  | 20,028
Lease liabilities, current | ​ | ​ | 1,791 | ​ | ​ | 1,691
Total Accrued and other current liabilities | ​ | $ | 13,101 | ​ | $ | 60,288
​ Other Liabilities, Non-current Other liabilities, non-current of continuing operations consisted of the following: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | September 30, |  | December 31,
(in thousands) | ​ | 2025 | ​ | 2024
Contingent consideration, non-current | ​ | $ | 102 | ​ | $ | 632
Deferred tax liability | ​ | ​ | 1,102 | ​ | ​ | 1,102
Revenue participation liability, non-current | ​ | ​ | 13,626 | ​ | ​ | 27,595
Royalty fee derivative liability, non-current | ​ | ​ | 1,490 | ​ | ​ | —
Other | ​ | ​ | 1,225 | ​ | ​ | —
Total Other liabilities, non-current | ​ | $ | 17,545 | ​ | $ | 29,329
​

X
- References No definition available. + Details
Name: | us-gaap_BalanceSheetRelatedDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration